Clinical characteristics of patients studied
| UPN . | M/F . | Age (y) . | Baseline T-Cell Function . | Time From Diagnosis (mo) . | Concurrent Treatment . | Baseline Anergy Screen* . | HLA Class 1 . | HLA Class 2 . | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 38 | nd | 21 | IFN | − | A2/A23 | B18 B41 | DR10/DR11/DR52 |
| 2 | M | 62 | Abnl-mix | 42 | HU/IFN | − | A1/A2 | B57 B65 | DR1/DR13/DR52 |
| 3 | F | 56 | Abnl-mix | 21 | IFN | − | A29 | B7 B38 | DR10/DR13 |
| 4 | M | 57 | Abnl-dec | 129 | HU | + | A11/A30 | B13 B52 | DR3/DR7 |
| 5 | M | 44 | Abnl-mix | 73 | HU | nd | A24/A3 | B62 B7 | DR15 |
| 6 | M | 73 | Abnl-dec | 1 | HU | + | A24/A24 | B13 B14 | DR1/DR7 |
| 7 | M | 29 | Abnl-dec | 5 | IFN | + | A33/A3 | B44 B58 | DR10/DR13 |
| 8 | F | 63 | Abnl-dec | 21 | HU/IFN | − | A3/A26 | B15 B49 | DR4/DR15 |
| 9 | M | 31 | nd | 69 | HU/IFN | + | A1/A2 | B15 B35 | DR14/DR3 |
| 10 | F | 51 | nd | 10 | HU/IFN | − | A3/A24 | B15 B44 | DR13/DR12 |
| 11 | M | 56 | Abnl-inc | 5 | HU/IFN | − | A2 | B18 B44 | DR12/DR13 |
| 12 | M | 65 | Abnl-inc | 31 | HU/IFN | − | A68/A2 | B40 B57 | DR7/DR4 |
| UPN . | M/F . | Age (y) . | Baseline T-Cell Function . | Time From Diagnosis (mo) . | Concurrent Treatment . | Baseline Anergy Screen* . | HLA Class 1 . | HLA Class 2 . | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 38 | nd | 21 | IFN | − | A2/A23 | B18 B41 | DR10/DR11/DR52 |
| 2 | M | 62 | Abnl-mix | 42 | HU/IFN | − | A1/A2 | B57 B65 | DR1/DR13/DR52 |
| 3 | F | 56 | Abnl-mix | 21 | IFN | − | A29 | B7 B38 | DR10/DR13 |
| 4 | M | 57 | Abnl-dec | 129 | HU | + | A11/A30 | B13 B52 | DR3/DR7 |
| 5 | M | 44 | Abnl-mix | 73 | HU | nd | A24/A3 | B62 B7 | DR15 |
| 6 | M | 73 | Abnl-dec | 1 | HU | + | A24/A24 | B13 B14 | DR1/DR7 |
| 7 | M | 29 | Abnl-dec | 5 | IFN | + | A33/A3 | B44 B58 | DR10/DR13 |
| 8 | F | 63 | Abnl-dec | 21 | HU/IFN | − | A3/A26 | B15 B49 | DR4/DR15 |
| 9 | M | 31 | nd | 69 | HU/IFN | + | A1/A2 | B15 B35 | DR14/DR3 |
| 10 | F | 51 | nd | 10 | HU/IFN | − | A3/A24 | B15 B44 | DR13/DR12 |
| 11 | M | 56 | Abnl-inc | 5 | HU/IFN | − | A2 | B18 B44 | DR12/DR13 |
| 12 | M | 65 | Abnl-inc | 31 | HU/IFN | − | A68/A2 | B40 B57 | DR7/DR4 |
Abnl-mix, increased and decreased functions (see Table 2); Abnl-dec, decreased in some functions (see Table 2); Abnl-inc, increased in some function (see Table 2); nd, not done; IFN, interferon-α; HU, hydroxyurea;
nonreactive to mumps or Candida skin test. +, >0.5 cm induration and erythema to mumps or Candida skin test.